But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...

defined by Kidney Disease: Improving Global Outcomes (KDIGO). While the findings showed higher kidney risk was associated with worse cardiovascular outcomes, the benefits of finerenone remained ...